Infographics

2022 AHA/ACC/HFSA Heart Failure Management Guidelines – Value Statements

2022 AHA/ACC/HFSA Heart Failure Management Guidelines - Value Statements This infographic outlines the economic value statements from the 2022 AHA/ACC/HFSA guidelines for heart failure management, helping to prioritize recommendations based on cost-effectiveness and quality of life impact. It categorizes treatments into high, intermediate, and low economic value, aiding clinicians in…

Continue Reading2022 AHA/ACC/HFSA Heart Failure Management Guidelines – Value Statements

Stage D (Advanced) Heart Failure

Stage D (Advanced) Heart Failure This infographic summarizes the 2022 AHA/ACC/HFSA Heart Failure Guidelines for Stage D, or advanced heart failure. It highlights indicators of advanced heart failure, including persistent symptoms despite guideline-directed medical therapy (GDMT), and therapeutic considerations for patients, such as inotropes, mechanical circulatory support (MCS), and transplant.…

Continue ReadingStage D (Advanced) Heart Failure

Aortic Stenosis

Read more about the article Aortic Stenosis
CardioNerds Aortic Stenosis, updated 1.20.21

Aortic Stenosis: Stages, Diagnosis, and Treatment Pathways This infographic offers a comprehensive visual guide to the stages of aortic stenosis (AS), from early risk to severe disease. It breaks down the progression through four key stages: Stage A: Individuals at risk of aortic stenosis (Vmax <2 m/s). Stage B: Progressive…

Continue ReadingAortic Stenosis

Mechanical Indications for Anticoagulation

Mechanical Indications for Anticoagulation This infographic outlines the recommended anticoagulation therapy for patients with mechanical and bioprosthetic valve replacements, as well as those with mechanical circulatory support. It covers INR goals, aspirin use, and bridging indications based on the presence of additional thrombotic risk factors and specific types of valve…

Continue ReadingMechanical Indications for Anticoagulation

Lp(a) and Cardiovascular Risk

Lp(a) and Cardiovascular Risk This infographic provides an overview of Lp(a) or lipoprotein(a), a genetically determined LDL-like particle associated with cardiovascular risk. The content covers biochemistry, genetics, manifestations, pathophysiology, therapeutic options, future directions in treatment, and clinical guidelines for measuring and evaluating Lp(a) levels. Produced by: Dr. Christian Faaborg AndersenEditors:…

Continue ReadingLp(a) and Cardiovascular Risk

Non-Statin Lipid Lowering Agents

Non-Statin Lipid Lowering Agents This table provides an overview of various non-statin lipid-lowering agents, summarizing their mechanisms, lipid-lowering efficacy, impact on major adverse cardiovascular events (MACE), advantages, and disadvantages. Drug Classes Covered: Bempedoic Acid Inclisiran PCSK9 Inhibitors (Evolocumab, Alirocumab) Ezetimibe Bile Acid Sequestrants Niacin Fibrates Omega-3 Fatty Acids (EPA) Each…

Continue ReadingNon-Statin Lipid Lowering Agents

Left Bundle Branch Block (LBBB)

Left Bundle Branch Block (LBBB) Overview:This infographic explains the etiology, risk factors, diagnostic criteria, mimics, and management strategies for Left Bundle Branch Block (LBBB). LBBB is a significant electrocardiographic abnormality indicating conduction delay through the left bundle branch, often linked to structural heart disease. Etiology: Fibrosis and degeneration due to…

Continue ReadingLeft Bundle Branch Block (LBBB)

End of content

No more pages to load